ziftomenib
ziftomenib is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Komzifti. Available dosage form: capsule.
Drug Details
- Generic Name
- ziftomenib
- Brand Names
- Komzifti
- Application Number
- NDA220305
- Sponsor
- Kura Oncology, Inc.
- NDC Codes
- 1
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- ZIFTOMENIB
Indications and Usage
1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 )